REVIEW PAPER
What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?
Submission date: 2018-02-23
Final revision date: 2018-03-29
Acceptance date: 2018-04-03
Online publication date: 2018-05-09
Publication date: 2018-04-30
Reumatologia 2018;56(2):106-110
KEYWORDS
TOPICS
ABSTRACT
Angiotensin receptor blockers or sartans are used to treat arterial hypertension. Hyperuricemia and arterial hypertension often coexist in patients with metabolic syndrome. Also hyperuricemia is correlated with an increased risk of cardiovascular disease and death. There are data suggesting that lowering serum urate may assist in control of arterial hypertension and use of certain drugs for arterial hypertension may reduce the serum uric acid level. The Polish Society of Arterial Hypertension recommends losartan for treatment of arterial hypertension in patients with coexisting hyperuricemia.
The aim of the present review was to find evidence supporting the concept of use and explain the role of sartans in treatment of hyperuricemia.
Thirty-five original and review articles about hyperuricemia and arterial hypertension focusing on the use of sartans in both these medical conditions were analyzed.
In conclusion, sartans should be recommended for treatment of hyperuricemia coexisting with arterial hypertension in patients without bilateral renal artery stenosis and with exclusion of pregnant women.
The aim of the present review was to find evidence supporting the concept of use and explain the role of sartans in treatment of hyperuricemia.
Thirty-five original and review articles about hyperuricemia and arterial hypertension focusing on the use of sartans in both these medical conditions were analyzed.
In conclusion, sartans should be recommended for treatment of hyperuricemia coexisting with arterial hypertension in patients without bilateral renal artery stenosis and with exclusion of pregnant women.
REFERENCES (36)
1.
Widecka K, Szymański FM, Filipiak KJ, et al. Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arter Hypertens 2017; 21: 1-9.
2.
Neogi T, Jansen K, Dalbeth N. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborate initiative. Ann Rheum Dis 2015; 74: 1789-1798.
3.
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42.
4.
Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64: 1431-1446.
5.
Swarowska-Knap J. Dna moczanowa – współczesny problem kliniczny. Medycyna po Dyplomie 2017; 1: 51-56.
6.
Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014; 73: 328-335.
8.
Peng F, Zhanf B, Zhong X, et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 2008; 14: 188-196.
9.
Chamarro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in pastients with acute stroke (URICO-ICUS): a randomised, double blind phase 2b/3 trial. Lancet Neurol 2014; 13: 453-460.
10.
Schretlen DJ, Inscore AB, Vannordsdall D, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418-1423.
11.
Tykarski A, Widecka K, Filipiak KJ. Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Próba komentarza na temat ich zasadności. Nadciśnienie Tętnicze w Praktyce 2015; 1: 71-94.
12.
Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc Bayl Univ Med Cent 2003; 16: 123-126.
13.
Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm 2001; 58: 671-683.
14.
Schlesinger A. New agents for the treatment of gout and hyperuricemia: febuxostat, puricase and beyond. Curr Rheum Rep 2010; 12: 130-134.
15.
Sundy JS, Baraf HS, Becker MA, et al. Efficacy and safety of intravenous (IV) pegloticase (PGL) in sublects with treatment failure gout (FG): phase 3 results from GOU1 and GOU2. Arthritis Rheum 2008; 58: S635.
16.
Goldman SC, Holcenberg JS, Finkelstein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998-3003.
17.
Li S, Yang H, Guo Y, et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systemic review and network meta-analysis. Sci Rep 2016; 6: 33-82.
18.
Basic and clinical pharmacology. Katzung BG (ed.). 6th ed. Appleton & Lange, Norwalk 1995: 536-559.
19.
Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
20.
Terkeltaub B, Furst DE, Bennett K, et al. Colchicine efficacy assessed by time to 50% reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial. Arthritis Rheum 2009; 59: S1108.
22.
et al. Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients. Ther Adv Cardiovasc Dis 2017; 11: 57-62.
23.
Ueno S, Hamada T, Taniguchi S, et al. Effect of Antihypertensive Drugs on Uric Acid Metabolism in Patients with Hypertension: Cross-Sectional Cohort Study. Drug Res 2016; 66: 628-632.
24.
Tykarski A, Narkiewicz K, Gaciong Z, et al. Zasady postepowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
25.
Kýrça M, Ođuz N, Çetin A, et al. Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFR. J Recept Signal Transduct Res 2017; 37: 167-173.
26.
Zhang JX, Zhang YP, Wu QN, et al. Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes. Endocrine 2015; 48: 135-142.
27.
Zheng H, Li N, Ding Y, et al. Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. Int J Clin Exp Pathol 2015; 8: 10428-10435.
28.
Shahataa MG, Mostafa-Hedeab G, Ali EF, et al. Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats. Can J Physiol Pharmacol 2016; 94: 907-917.
29.
Motozato K, Miura S, Shiga Y, et al. Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study). Clin Exp Hypertens 2016; 38: 45-50.
30.
Chida R, Hisauchi I, Toyoda S, et al. Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients. Hypertens Res 2015; 38: 765-769.
31.
Ishimitsu T, Fukuda H, Uchida M, et al. The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; safety and efficacy in patients with hypertension) study. Clin Exp Hypertens 2015; 37: 542-550.
32.
Fan Y, Wei F, Lang Y, et al. Losartan treatment for hypertensive patients with hyperuricemia in Chinese population: a meta- analysis. J Hypertens 2015; 33: 681-688.
33.
Pérez Carreńo JG, Romero JD, Villar Centeno JC. METAL Study Investigators. Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study). Ther Adv Cardiovasc Dis 2013; 7: 237-245.
34.
Hosoya T, Kuriyama S, Yoshizawa T, et al. Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. Intern Med 2012; 51: 2509-2514.
35.
Hosoya T, Kuriyama S, Ohno I, et al. Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. Clin Exp Nephrol 2012; 16: 269-278.
36.
Rycombel A, Lomper K, Uchmanowicz I. Adherence i compliance w leczeniu nadciśnienia tętniczego. Nadciśnienie Tętnicze 2014; 18: 151-158.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
